The immune response after heterologous COVID-19 vaccine administration in healthy volunteers. COVID-19 vaccine, heterologous prime-boost, ChAdOx1, coronavac, Sinovac.
Conditions
Interventions
Administration CoronaVac 0.5 ml intramuscular at deltoid muscle then AZD1222 0.5 ml intramuscular at deltoid muscle with a 4-week interval.,Administration AZD1222 0.5 ml intramuscular at deltoid muscl
CoronaVac/AZD1222,AZD1222/CoronaVac,AZD1222/AZD1222
Sponsors
Chulabhorn Royal Academy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. 18 years old or more 2. Negative urine pregnancy test (in case of potential of pregnancy) 3. No history of a severe allergic reaction to the prior vaccine. 4. No fever nor history of fever within 14 days. 5. No symptoms of respiratory tract infection within 14 days. 6. sign informed consent to the study.
Exclusion criteria
Exclusion criteria: 1. prior COVID-19 vaccination. 2. pregnancy. 3. lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Humoral immunity 4 weeks after boosted dose 4 weeks after the boosted dose of the vaccine Double antigen technique for detection of Antibody level of total antibody of spike protein of SARS-CoV-2 | — |
Secondary
| Measure | Time frame |
|---|---|
| proportion of seroconversion after vaccination 4 weeks after the boosted dose of the vaccine Double antigen technique for detection of Antibody level of total antibody of spike protein of SARS-CoV-2,Safety profile after vaccination in each intervention arms 4 week after each dose of vaccine Solicited adverse events | — |
Countries
Thailand
Contacts
Public ContactKriangkrai Tawinprai
HRH Princess Chulabhorn College of Medical Science
Outcome results
None listed